Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | PPARA | Q07869 | 8/20 | 0.47 |
| ▸ | PPARD | Q03181 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620765 | 0.89 | PPARA (0.55) | PPARGPPARAPPARDEPHX2FFAR1 | |
| SCHEMBL6818759 | 0.84 | PPARG (0.48) | PPARGPPARAPPARDEPHX2FFAR1 | |
| SCHEMBL5992000 | 0.82 | PPARG (0.50) | PPARGPPARAPPARDEPHX2FFAR1 | |
| SCHEMBL3660194 | 0.81 | LTA4H (0.65) | PPARGPPARAPPARDFFAR1LMNA | |
| SCHEMBL6817962 | 0.79 | IL1RN (0.52) | PPARGLMNAACACBALDH1A1 | |
| SCHEMBL6817956 | 0.79 | IL1RN (0.52) | PPARGLMNAACACBALDH1A1 | |
| SCHEMBL6821634 | 0.78 | FFAR1 (0.40) | PPARGPPARAFFAR1LMNAL3MBTL1 | |
| SCHEMBL28201178 | 0.78 | EPHX2 (0.64) | PPARGPPARAPPARDEPHX2 | |
| SCHEMBL3662079 | 0.76 | ESR1 (0.61) | PPARGEPHX2 | |
| SCHEMBL13078733 | 0.76 | ESR1 (0.61) | PPARGEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARG 47/4885PPARA 74/4885PPARD 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.